We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD , senior vice president of clinical development, medical and regulatory affairs at Novo Nordisk
First, insulin support helps move glucose from the blood into cells
This is the therapeutic dose
You may still be going slightly more often than before tirzepatide, but it is no longer disruptive
These two medications work through fundamentally different mechanisms, and treating the transition like a direct conversion is one of the most common mistakes people make
He described STRIDE as a practice-changing trial and cheered the long-term impact semaglutide could have on the lifestyles of these patients